Valneva: successful homogeneity trial for chikungunya
(CercleFinance.com) - Valneva announces the successful completion of the Phase 3 trial to assess the homogeneity of clinical batches of its chikungunya vaccine candidate, VLA1553, with the final analysis including six-month follow-up data confirming the initial results from December 2021.
The VLA1553-302 trial has met its primary endpoint, demonstrating that three consecutively manufactured batches elicited equivalent immune responses, measuring neutralising antibody titers 29 days after vaccination.
The trial, which included 408 participants aged 18-45 years, confirmed the very good immunogenicity profile demonstrated in the VLA1553-301 trial. All three batches were well tolerated and the safety profile was consistent with previous results.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The VLA1553-302 trial has met its primary endpoint, demonstrating that three consecutively manufactured batches elicited equivalent immune responses, measuring neutralising antibody titers 29 days after vaccination.
The trial, which included 408 participants aged 18-45 years, confirmed the very good immunogenicity profile demonstrated in the VLA1553-301 trial. All three batches were well tolerated and the safety profile was consistent with previous results.
Copyright (c) 2022 CercleFinance.com. All rights reserved.